Suma Krishnan - Feb 26, 2022 Form 4 Insider Report for Krystal Biotech, Inc. (KRYS)

Role: President, R&D, Director, 10%+ Owner
Signature: /s/ Suma Krishnan
Stock symbol: KRYS
Transactions as of: Feb 26, 2022
Transactions value $: -$205,125
Form type: 4
Date filed: 3/1/2022, 08:20 PM
Previous filing: Dec 14, 2021
Next filing: Aug 9, 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KRYS	Common Stock	Tax liability	-$205K	-3.28K	-0.19%	$62.50	1.75M	Feb 26, 2022	Direct	F1, F2
holding	KRYS	Common Stock						1.81M	Feb 26, 2022	By Spouse	F3
holding	KRYS	Common Stock						90K	Feb 26, 2022	By SMK Trust
holding	KRYS	Common Stock						50K	Feb 26, 2022	By Krishan Family Trust	F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KRYS	Stock Option (Right to Buy)	Award	$0	+50K		$0.00	50K	Feb 28, 2022	Common Stock	50K	$63.55	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents tax withholding upon the vesting of 7,100 shares of restricted stock on February 26, 2022.
F2	The closing price on February 25, 2022 of the Company's common stock on NASDAQ.
F3	Directly beneficially owned by Krish S. Krishnan, the spouse of the reporting person.
F4	Directly beneficially owned by the Krishnan Family Trust. The reporting person and her spouse are each joint beneficial owners of the trust with joint voting and investment control.
F5	The option vests in four equal annual installments beginning on February 28, 2023.